Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
In a blinded randomized clinical trial, which will include health workers (doctors,
residents, nurses, stretcher-bearers, technicians, hygiene and cleaning) who are members of
the health teams that care for patients with COVID-19. Two groups will be formed: the Vitamin
D group taking 4,000 IU orally daily for 30 days, the control group being given a placebo
during the same time period.
Participants will be adults, who have not had COVID-19 disease, and who sign the informed
consent. At the beginning of the study anthropometric variables (weight, height, BMI) will be
taken, the short medical history can be identified to identify comorbidities, and a fasting
blood sample will be taken to determine changes in Vitamin D (25 (OH) Vitamin D), in addition
to RT-PCR saliva samples, as well as detection of serum antibodies to determine whether or
not they have SARS-CoV-2 disease. Participants will follow each other 45 days. Those with
COVID-19 disease will be monitored frequently to determine the course of the disease. At the
end of 45 days, new samples will be taken to determine levels of vitamin D and antibodies
against SARS-Cov-2.